Comparison of prognostic values of primary tumor and nodal 18F-fluorodeoxyglucose uptake in non-small cell lung cancer with N1 disease
- 34 Downloads
We hypothesized that, in non-small cell lung cancer (NSCLC) with N1 metastasis, N1 nodal 18F-fluorodeoxyglucose (FDG) status offers independent and incremental prognostic value.
We enrolled 106 NSCLC patients with pathology-confirmed N1 metastasis. N1 node FDG positivity, primary tumor maximum standard uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Kaplan-Meier method and Cox regression analyses were performed for cancer-specific survival (CSS) and disease-free survival (DFS).
Subjects were 67 males and 39 females (61.9 ± 9.4 years). Eighty-one (76.4%) and 25 (23.6%) had pathologic stage IIB and IIIA NSCLC, respectively. All underwent complete tumor resection. FDG-positive N1 nodes were larger and had higher primary tumor SUVmax. During a follow-up of 42 months, there were 56 recurrences and 31 cancer deaths. Significant univariate predictors were stage, no adjuvant therapy, and FDG-positive nodes for DFS, and stage, no adjuvant therapy, node size, tumor MTV, TLG, and SUVmax, and FDG-positive nodes for CSS. Independent predictors on multivariate analyses were FDG-positive nodes (HR = 3.071, p = 0.003), greater tumor TLG (HR = 3.224, p = 0.002), and no adjuvant therapy (HR = 3.631, p < 0.001) for poor CSS, and FDG-positive nodes (HR = 1.771, p = 0.040) and no adjuvant therapy (HR = 2.666, p = 0.002) for poor DFS. Harrell’s concordance and net reclassification improvement tests showed that CSS prediction was significantly improved by the addition of N1 FDG status to a model containing tumor TLG.
N1 node FDG status can be useful for predicting the outcome of NSCLC patients with N1 metastasis beyond that provided by other prognostic variables.
• In NSCLC with N1 disease, N1 node FDG status is useful as a prognostic predictor.
• FDG-positive N1 nodes provide additional prognostic value beyond TLG of primary tumor.
• Combining TLG of primary tumor and N1 node uptake can stratify the survival of patients.
KeywordsLung cancer Positron emission tomography Fluorodeoxyglucose F18 Lymph nodes
Eastern Cooperative Group
Metabolic tumor volume
Net reclassification improvement
Non-small cell lung cancer
Positron emission tomography/computed tomography
Receiver operating characteristics
Maximum standard uptake value
Total lesion glycolysis
This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (# 2016R1C1B2013411).
Compliance with ethical standards
The scientific guarantor of this publication is Kyung-Han Lee.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
This work was supported by Kyunga Kim, Biostatics, Samsung Medical Center.
Written informed consent was waived by the Institutional Review Board.
Institutional Review Board approval was obtained.
• Diagnostic or prognostic study
• Performed at one institution
- 2.Asamura H, Chansky K, Crowley J et al (2015) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 10:1675–1684CrossRefGoogle Scholar
- 5.Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y (1994) Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes. J Thorac Cardiovasc Surg 107:1398–1402Google Scholar
- 6.van Velzen E, Snijder RJ, Brutel de la Riviere A, Elbers HJ, van den Bosch JM (1996) Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Lymph node involvement by direct extension compared with lobar and hilar node metastases. Chest 110:1469–1473CrossRefGoogle Scholar
- 13.Yoo Ie R, Chung SK, Park HL et al (2014) Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis. Biomed Mater Eng 24:3091–3103Google Scholar
- 16.FE H (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. SpringerGoogle Scholar
- 22.Vansteenkiste JF, Stroobants SG, Dupont PJ et al (1999) Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17:3201–3206CrossRefGoogle Scholar
- 29.Kaseda K, Watanabe K, Asakura K, Kazama A, Ozawa Y (2016) Identification of false-negative and false-positive diagnoses of lymph node metastases in non-small cell lung cancer patients staged by integrated (18F-)fluorodeoxyglucose-positron emission tomography/computed tomography: a retrospective cohort study. Thorac Cancer 7:473–480CrossRefGoogle Scholar
- 32.Higashi K, Ueda Y, Yagishita M et al (2000) FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 41:85–92Google Scholar
- 34.Vesselle H, Schmidt RA, Pugsley JM et al (2000) Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6:3837–3844Google Scholar